Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

35.19 +0.98 (+2.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,036,613
Open 35.00
Bid (Size) 35.30 (6)
Ask (Size) 37.36 (2)
Prev. Close 34.21
Today's Range 34.70 - 36.66
52wk Range 32.96 - 55.80
Shares Outstanding 95,161,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations for Cytokinetics's Future
 
Via Benzinga
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga

Performance

YTD
-20.65%
-20.65%
1 Month
-11.14%
-11.14%
3 Month
-20.65%
-20.65%
6 Month
-31.15%
-31.15%
1 Year
-8.31%
-8.31%

More News

Read More
Analyst Ratings for Cytokinetics
Via Benzinga
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
Via Benzinga
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate
Via Benzinga
Earnings Scheduled For March 1, 2023
Via Benzinga
Cytokinetics's Earnings: A Preview
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Expert Ratings for Cytokinetics
Via Benzinga
What 7 Analyst Ratings Have To Say About Cytokinetics
Via Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023
Via Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
Via Investor's Business Daily
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
Via Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.